Belgian drugmaker UCB (Euronext: UCB) and US biotech Biogen’s (Nasdaq: BIIB) Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48.
With a novel CD40L-targeting mechanism and favorable efficacy outcomes, this therapy has the potential to challenge established SLE treatments and address unmet needs in an increasingly competitive therapeutic landscape, according to pharma analytics company GlobalData.
The findings of this trial, which constitute a significant milestone for the companies, which will debut as a late-breaking abstract at the upcoming American College of Rheumatology (ACR) 2024 congress, taking place on November 14-19, 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze